Skip to main
PRME
PRME logo

PRME Stock Forecast & Price Target

PRME Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 43%
Buy 36%
Hold 21%
Sell 0%
Strong Sell 0%

Bulls say

Prime Medicine Inc. is projected to achieve significant revenue growth, with anticipated risk-adjusted revenues reaching $980 million by 2035, an increase from $32 million in 2030. The company is advancing its PM577 program for Wilson’s Disease towards clinical trials, which presents a favorable commercial opportunity due to its innovative GalNAc-targeting ligand LNP technology and solid data from preclinical models. Additionally, the anticipated positive clinical data from PM359 and the promising developments in the in vivo gene editing franchise are expected to heighten investor interest in Prime Medicine's capabilities and its potential to address high unmet medical needs in genetic therapies.

Bears say

Prime Medicine Inc faces a negative outlook primarily due to significant uncertainties surrounding the regulatory approval process for its gene editing technologies, which could lead to downward revisions in financial projections if products do not gain approval. Additionally, the company's ability to recruit eligible patients for clinical trials may hinder the development of its therapies, further complicating future financial forecasts. Finally, concerns regarding the high potential pricing of Prime's therapies and safety issues associated with gene editing technologies could create substantial barriers to market acceptance and overall success, impacting the company's financial viability.

PRME has been analyzed by 14 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 36% recommend Buy, 21% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prime Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prime Medicine Inc (PRME) Forecast

Analysts have given PRME a Buy based on their latest research and market trends.

According to 14 analysts, PRME has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prime Medicine Inc (PRME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.